Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002173 | 0.85 | TSHR (0.60) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL13431424 | 0.83 | TSHR (0.62) | CYP3A4TSHRARSMN1; SMN2PGR | |
| SCHEMBL15724709 | 0.82 | MAPK1 (0.59) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL29788520 | 0.79 | ATM (0.60) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL1998640 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL4310481 | 0.79 | ALDH1A1 (0.53) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL377777 | 0.79 | ATM (0.60) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL31138869 | 0.79 | ALDH1A1 (0.53) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL2639009 | 0.79 | SIRT6 (0.51) | CYP3A4TSHRSIRT6ARLMNA | |
| SCHEMBL13208348 | 0.79 | AR (0.54) | CYP3A4TSHRSIRT6ARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3331852-B1 | SUBSTITUTED MALONAMIDES AND THEIR USE AS ANTIBACTERIAL DRUGS | UNIV NAT TAIWAN (TW) | 2020-12-23 | — | — | EP | disclosed |
| US-10800732-B2 | Substituted malonamides and their use as antibacterial drugs | NATIONAL TAIWAN UNIVERSITY (TW) | 2020-10-13 | — | — | US | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-7214693-B2 | Heterocyclic selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214693-B2 | Heterocyclic selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1775289-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-4749813-A | 4-alkyl-2-trifluoromethylanilines | BAYER AKTIENGESELLSCHAFT (DE) | 1988-06-07 | — | — | US | disclosed |
| EP-0084320-B1 | 4-ALKYL-2-TRIFLUOROMETHYL ANILINES | BAYER AG (DE) | 1985-08-28 | — | — | EP | disclosed |
| EP-0084320-A2 | 4-Alkyl-2-trifluoromethyl anilines | BAYER AG (DE) | 1983-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | CYP3A4 4880/4885TSHR 1037/4885SIRT6 4132/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | CYP3A4 2058/4885TSHR 1939/4885SIRT6 3032/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | CYP3A4 2041/4885TSHR 3558/4885SIRT6 1069/4885 |
| US-10800732-B2 | Substituted malonamides and their use as antibacterial drugs | NAAA, MAL2, MGAM | CYP3A4 982/4885TSHR 4749/4885SIRT6 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.